Journal of Cancer Therapy

Volume 4, Issue 8 (September 2013)

ISSN Print: 2151-1934   ISSN Online: 2151-1942

Google-based Impact Factor: 0.53  Citations  h5-index & Ranking

Advances in Lung Cancer and Treatment Research

HTML  Download Download as PDF (Size: 158KB)  PP. 36-43  
DOI: 10.4236/jct.2013.48A006    3,752 Downloads   5,486 Views  


With the advances in surgery, chemotherapy, and radiotherapy over the last decades, the treatment strategies of lung cancer has been largely changed. In this review, we summarize recent advances in lung cancer and treatment research. We discuss current clinical management, highlight stage-specific therapy approaches, chemotherapy options for advanced-stage of non-small-cell lung cancer (NSCLC) patients, along with new agents such as epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors erlotinib and gefitinib, and the anaplastic lymphoma kinase (ALK) inhibitor crizotinib. We also give an outlook into NSCLC disease biology, focuse on the importance of EGFR activating mutations and the role of the tumor-microenvironment. Finally we summarize the new recommendations in treating small-cell-lung cancer (SCLC).

Share and Cite:

Wang, X. and Han, B. (2013) Advances in Lung Cancer and Treatment Research. Journal of Cancer Therapy, 4, 36-43. doi: 10.4236/jct.2013.48A006.

Cited by

No relevant information.

Copyright © 2021 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.